Provided are a microorganism that produces a diamine compound and a method of producing a diamine compound.

The genetically modified microorganism expresses an enzyme involved in synthesis of a diamine compound, in which the diamine compound is represented by Formula: H.sub.2N—R—NH.sub.2 (wherein, R is a chain or cyclic organic group comprised of one or more atoms selected from the group consisting of C, H, O, N, and S), and the genetically modified microorganism is modified to reduce an activity of an alcohol dehydrogenase compared to a non-reduced strain.

The present invention relates to a protein variant, a microorganism with enhanced carbon monoxide (CO) availability comprising the variant, and a use thereof.

Provided herein are methods, compositions, and non-naturally occurring microbial organism for preparing compounds such as α-butanol, butyric acid, succinic acid, 1,4-butanediol, 1-pentanol, pentanoic acid, glutaric acid, 1,5-pentanediol, 1-hexanol, hexanoic acid, adipic acid, 1,6-hexanediol, 6-hydroxy hexanoic acid, ε-Caprolactone, 6-amino-hexanoic acid, ε-Caprolactam, hexamethylenediamine, linear fatty acids and linear fatty alcohols that are between 7-25 carbons long, linear alkanes and linear α-alkenes that are between 6-24 carbons long, sebacic acid and dodecanedioic acid comprising: a) converting a C.sub.N aldehyde and pyruvate to a C.sub.N+3 β-hydroxyketone intermediate through an aldol addition; and b) converting the C.sub.N+3 β-hydroxyketone intermediate to the compounds through enzymatic steps, or a combination of enzymatic and chemical steps.

The present disclosure belongs to the field of bioengineering, and relates to breeding of industrial microorganisms, in particular to a genetically engineered strain of Saccharomyces cerevisiae, method for constructing the same, and its use for brewing, the genetically engineered strain of Saccharomyces cerevisiae heterogeneously overexpresses an acetaldehyde dehydrogenase gene ALD6, an acetyl-CoA synthase gene ACS1 and an alcohol acyltransferase gene AeAT9. The Saccharomyces cerevisiae strain with high yield of ethyl acetate and low yield of higher alcohols provided by the present disclosure not only maintains excellent ethanol fermentation characteristics, but also reducing the production of higher alcohols which adversely affect the comfort after drinking, which is of great significance for a well-maintained and strengthened flavor characteristics of Chinese Baijiu, an improved and stabilized quality thereof, and even a reform in the fermentation process thereof.

Provided herein are systems and methods for the production of malonic acid or a salt thereof in recombinant host cells.

A combination of an electrochemical device for delivering reducing equivalents to a cell, and engineered metabolic pathways within the cell capable of utilizing the electrochemically provided reducing equivalents is disclosed. Such a combination allows the production of commodity chemicals by fermentation to proceed with increased carbon efficiency.

A nanoparticle (for example, quantum dot) serves as a substrate for immobilizing enzymes involved in consecutive reactions as a cascade. This results in a significant increase in the rate of catalysis as well as final product yield compared to non-immobilized enzymes.

Described herein is a method for producing a transgenic cell product wherein the gene of interest is operably linked to an inducible promoter other than AOX1. Production of the transgenic cell product is activated when the host cell is grown on a non-repressing carbon source for de-repressing the inducible promoter and an amount of an inducer compound selected from the group consisting of: formaldehyde; S-formylglutathione; S-hydroxymethyl glutathione; formic acid; an alkali metal salt of formic acid; and an alkaline earth metal salt of formic acid; sufficient to induce the inducible promoter is added to the host cell culture.

The present invention relates to compositions comprising one or more polypeptide(s) comprising or consisting of a sequence of SEQ ID NO. 1-14 or a sequence having a sequence identity of at least 75% to any one of SEQ ID NO. 1-14 and a carrier as well as uses and methods of these polypeptides.

Provided herein are combination therapies involving co-expression of an E2 subunit of a branched-chain alpha-keto acid dehydrogenase (BCKDH) from a skeletal muscle-targeted rAAV.hDBT vector and a liver-targeted rAAV.hDBT vector. Also provided herein are combination therapies wherein an E1a and/or an E1b subunit of the BCKDH complex is expressed from muscle and/or liver following rAAV-mediated delivery targeted to these tissues. Further provided is a pharmaceutical composition comprising a rAAV as described herein in a formulation buffer, and a method of treating a human subject diagnosed with MSUD.